Subscribe
shutterstock_1017347380_sundryphotography
sundryphotography / Shutterstock.com
24 September 2020AmericasSarah Morgan

Genmab locked in J&J royalty payments dispute

Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
J&J, HHS sign expanded deal to find COVID-19 vaccine
14 February 2020   Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Medtech
Conformis launches implant lawsuit against J&J subsidiary
4 May 2021   US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
J&J, HHS sign expanded deal to find COVID-19 vaccine
14 February 2020   Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Medtech
Conformis launches implant lawsuit against J&J subsidiary
4 May 2021   US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.

More on this story

Big Pharma
J&J, HHS sign expanded deal to find COVID-19 vaccine
14 February 2020   Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Medtech
Conformis launches implant lawsuit against J&J subsidiary
4 May 2021   US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?